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Alkylating cytostatics belonging to the group
of oxazaphosphorines (cyclophosphamide ñ CP,
ifosfamide ñ IF) are broadly used in chemotherapy
of cancer (both solid tumors and proliferative condi-
tions of the hematopoietic system), and in pharma-
cotherapy of chronic inflammatory diseases and
autoimmune conditions (primary systemic vasculi-
tis, visceral lupus, periarteritis nodosa) (1, 2).
General adverse effects of those agents include nau-
sea and vomiting, alopecia, hypersensitivity reac-
tions and myelosuppression (3). Long-term adminis-
tration of CP/IF is associated with a toxic effect on
gonads and sterility, and with a paradoxically
increased risk of many types of cancer (prostatic,
pulmonary, cystic, breast, endometrial, thyroid,
hepatic, gastric) (4). Moreover, chronic use of large
CP/IF doses (on the level of 60 mg/kg a day) result-
ed in development of myocarditis, increased
arrhythmogenesis and congestive heart failure, and
with interstitial pulmonary fibrosis (4, 5). In case of
ifosfamide, a neurotoxic effect was also reported,
manifested with signs of encephalopathy, usually
disappearing following completion of the treatment
(6, 7). 
One of the most significant adverse drug reac-
tions (ADR) associated with oxazaphosphorines,
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Abstract: Oxazaphosphorines (cyclophosphamide ñ CP, ifosfamide ñ IF) are alkylating cytostatics used in
chemotherapy of cancer and autoimmune diseases. They have numerous adverse effects, including uro- and
nephrotoxic, dependent of the type of drug, time of therapy and presence of any coexistent nephrotoxic factors
in a treated patient. Purpose of this study was to estimate the renal function and the level of urinary bladder dys-
function occurring in rats following administration of a single, large CP/IF dose. The experiment involved 30
rats who were administered a single intraperitoneal dose of 150 mg/kg b.w. of CP (group 1) or IF (group 2) or
normal saline (group 3 ñ control), respectively. Following the administration animals were placed in individual
metabolic cages. 24 h later rats were sacrificed, blood collected and nephrectomy and cystectomy performed in
order to prepare specimens for histopathological analysis. Circadian diuresis was also assessed, along with a
qualitative urine assessment with strip tests and laboratory renal function parameters in plasma and urine: sodi-
um, urea, creatinine and uric acid levels, and circadian elimination of sodium, potassium, urea, creatinine, uric
acid and protein. Creatinine clearance, urea clearance and fractionated sodium elimination (FENa) and renal
failure index (RFI) were also calculated. An increased diuresis and acidification of urine with reduced circadi-
an elimination of potassium and a significant proteinuria, as well as increased plasma levels of creatinine and
urea were found in the group of rats that received a single dose of CP, compared to control animals. Rats treat-
ed with IF also demonstrated acidification of urine, reduced circadian potassium elimination, a significant pro-
teinuria and increased plasma creatinine and urea levels, but their diuresis was comparable to that observed in
control animals. IF-treated animals were also characterized by reduced urea clearance, FENa and RFI.
Histopathological analysis confirmed presence of inflammatory changes in urinary bladders in both groups 1
and 2, and absence of any significant morphological disorders in kidneys. Obtained results suggest a dysfunc-
tion of distal tubules and collective tubules developing as a result of administration of a single nephrotoxic dose
of IF/CP. FENa and RFI results indicate also a higher nephrotoxic potential of IF administered as a single dose.
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and particularly with cyclophosphamide, is hemor-
rhagic cystitis initiated by urotoxic acrolein released in
course of CP/IF metabolism. The endogenous, hepatic
bio-transformation of cyclophosphamide is based
mostly on cytochromes CYP2B6, CYP2C9 and
CYP3A4 (8). Metabolism of cyclophosphamide with
those cytochromes leads to final production of a 4-
hydroxy derivative, that undergoes conversion to
aldophosphamide releasing nitrogen mustard ñ a com-
pound attributed the main cytostatic and alkylating
properties of cyclophosphamide (8). Acrolein is also
formed in course of those transformations. It is a high-
ly reactive, α,β-unsaturated aldehyde that causes
reduction of the intracellular level of glutathione and of
other compounds containing thiol groups, and combin-
ing with nucleophilic compounds. Acrolein is a strong
inducer of lipid peroxidation, and changing the intra-
cellular redox balance leads to dysregulation of
cytokines that participate in inflammatory processes,
proliferation and apoptosis (9). In the urinary bladder
the compound induced a cascade of inflammatory
changes, release of numerous proinflammatory media-
tors and free radicals that damage the urothelium. This
disturbance is characteristic particularly to cyclophos-
phamide, as its chemical structure makes it specifical-
ly prone to acrolein generation. A detailed pathophysi-
ological description of oxazaphosphorine-triggered
cystitis may be found in review articles (3, 10-13),
including the one published by us (14). Similarly,
another significant ADR characteristic for CP/IF is
nephrotoxicity. Its pathogenesis is also associated with
effects dependent on acrolein, synthesized with
cytochromes CYP2B6 (15, 16) and CYP2C9 (17),
present also in extrahepatic tissues, e.g., in kidneys.
Chloroacetic aldehyde, released along with
acrolein as a result of biotransformation of oxaza-
phosphorines in course of renal injury, is nephrotox-
ic, especially for proximal and collecting renal
tubules. The compound intensifies the unfavorable
effect of acrolein causing impairment of function of
cells in renal tubules by further reduction of glu-
tathione, acetyl-coenzyme A and ATP levels, and
block of the enzymatic complex of NADH
ubiquinone oxidoreductase ñ a component of the
mitochondrial respiratory chain (3). Considering the
fact that during its bio-transformation ifosfamide gen-
erates 40-times more acetic aldehyde than the similar
dose of cyclophosphamide, it is believed that nephro-
toxicity is a principal, although not sole, adverse
effect of that oxazaphosphorine derivative (18). 
A clinical manifestation of nephrotoxic effect of
oxazaphosphorines covers a broad spectrum of disor-
ders dependent on the type of drug (CP/IF), dose,
administration route, time of therapy and some addi-
tional factors (patient age, coexistence of other
nephrotoxic factors). Literature data indicate develop-
ment of both glomerulopathy and tubulopathy, and
even of renal failure in CP/IF-treated patients (19, 20).
Considering a variable character of renal dys-
functions and the fact that ñ as mentioned above ñ
nephrotoxicity is a common ADR observed for both
agents (although more characteristic for IF, as cysti-
tis is the dominating adverse effect of CP), the aim
of the study was to estimate the renal function and
the level of urinary bladder injury in rats receiving a
single, large dose of CP/IF.
EXPERIMENTAL
The medical experiment described in this paper
was approved by the 1st local Ethical Commission
in Krakow (No. 1/2016). The experiment was con-
sistent with the EU Directive 2010/63 on the protec-
tion of animals used for scientific purposes and with
the Polish legislation ñ The Law of 15 January 2015
on the protection of animals used for scientific or
educational purposes (Journal of Laws, 26 February
2015, item 266). 
Test groups of animals
Ten-week old (mature) albino Wistar rats of
both sexes in equal proportions, with initial body
weight of 243.3 g were used in the experiment.
Animals were obtained from the Central Animal
House of the Pharmaceutical Faculty of the UJCM.
After being transported to the local Animal House of
the Chair of Pathophysiology UJCM, animals were
acclimatized for 7 days. During that time they were
kept in collective cages of five animals of the same
sex. Duration of acclimatization was consistent with
literature data recommending the period of 5-15
days (21). Animals were handled and clinically
observed during that period. On the day 8, animals
were transferred to a collective pen and randomized
into study groups (of 10 animals each, with an equal
proportion of both sexes):
Group 1 ñ rats receiving cyclophosphamide at
the single dose of 150 mg/kg b.w.
Group 2 ñ rats receiving ifosfamide at the sin-
gle dose of 150 mg/kg b.w.
Group 3 ñ control ñ rats receiving normal
saline
All animals completed the study. Therefore, 30
animals participated in the experiment.
Plan of the experiment
The principal part of the experiment was com-
pleted using metabolic cages allowing measurement
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of circadian diuresis and consumption of feed, in an
air-conditioned pen at constant temperature of 22OC
and relative humidity of 60%, with a 12/12 h
day/night cycle (light phase 8 a.m. ñ 8 p.m; dark
phase 8 p.m. ñ 8 a.m.). Following intraperitoneal
administration of CP/IF/normal saline, respectively,
to animals in groups 1, 2 and 3, study animals were
placed in individual metabolic cages for 24 hours,
with unlimited but monitored access to water and
standard feed (Labofeed, Kcynia, Poland). Before
administration of a drug/normal saline animals were
weighed using a standard laboratory scales in order
to determine the required CP/IF dose and placed in
a tamer for rectal measurement of body temperature
using a digital thermometer for rodents (Vivari,
UK). Selection of the dose of 150 mg/kg b.w. for the
applied nephrotoxic CP dose was consistent with lit-
erature data, recommending a single administration
of 100 mg/kg b.w. (22), 150 mg/kg b.w. (23, 24), or
200 mg/kg b.w. (25, 26) as the amount causing a
sub-lethal toxic effect in rats. On the same basis, the
recommended single nephrotoxic dose of IF used for
experimental purposes ranges between 60-240 in
rabbits (27) to as much as 400 mg/kg b.w. in mice
(28). Adoption of that dosage regimen results with
acute urinary bladder injury developing within 4 ñ
24 h after CP/IF administration. Both CP and IF
were purchased from Sigma Aldrich in crystalline
form. Individual doses were prepared by reconstitu-
tion in 0.5 mL of normal saline and mixing with a
vortex (directly before administration) of an analyt-
ically weighed dose calculated according to the
body weight of a given animal. Animals in the con-
trol group received an intraperitoneal injection with
pure normal saline at the same volume of 0.5 mL, as
the volume for animals in groups 1 and 2. Keeping
animals is metabolic cages allowed the assessment
of the following parameters within 24 h after admin-
istration of CP/IF/normal saline: body weight [g]
(determined by subsequent weighing on an analyti-
cal scales), body temperature [OC] (as indicated by
subsequent rectal measurement), circadian water
consumption [mL/24 h], circadian feed consumption
[g/24 h] and circadian diuresis [mL/24 h]. After
daily urine output was measured, urine was ana-
lyzed using strip tests. Urine was subsequently cen-
trifuged (Heraeus Instruments Megafuge 1.0 R; 2000
rpm ñ 719 g for 5 min), and divided into portions.
Resulting samples were stored at -20OC until labora-
tory determinations completed with the ADVIA
1200 SIEMENS analyzer. Sodium [mM/L], potassi-
um [mM/L], creatinine (Cr) [mM/L], uric acid
[µM/L] and protein [g/L] levels were determined.
Having results of circadian diuresis, circadian elimi-
nation of sodium, potassium, urea [mM/24 h], uric
acid, creatinine [µM/24 h] and protein [mg/24 h]
with urine was calculated. Creatinine clearance was
also estimated, according to the formula:
CLcr = Cr urine [µM/L] ◊ diuresis [mL/min] /
Cr plasma [µM/L]
Urea clearance was calculated according to the
formula:
CLurea = urea urine [mM/L] ◊ 
diuresis [mL/min] / urea plasma [mM/L]
Fractional excretion of sodium (FENa) was cal-
culated using the formula:
FENa = [(Na urine [mM/L] ◊ Cr plasma [µM/L]) ◊
100] / [(Na plasma [mM/L] ◊ Cr urine [µM/L])]
The renal failure index (RFI) was calculated
with the formula:
RFI = [(Na urine [mM/L] ◊ Cr plasma [µM/L])] / 
Cr urine [µM/L]
After the period of monitoring in metabolic
cages animals were deeply anesthetized by intraperi-
toneal administration of 60 mg/kg b.w. of sodium
pentobarbital (Morbital; Biowet, Pu≥awy). Under
general anesthesia blood was collected from the
heart in amount allowing completion of all planned
laboratory plasma determinations, and study rats
were sacrificed by repeated intraperitoneal adminis-
tration of lethal dose of sodium pentobarbital (200
mg/kg b.w.). Similarly to urine, collected blood was
centrifuged and resulting plasma samples were kept
frozen for the time of laboratory determinations.
Sodium, potassium, urea [mM/L] and creatinine
(Cr) and uric acid [µM/L] levels were determined in
plasma with the same analyzer as the one used for
urine samples. Protein was not assayed in plasma.
After definitive cease of vital signs, cystectomy and
nephrectomy was performed in study animals in
order to obtain tissue necessary for subsequent
histopathological assessment of kidneys and urinary
bladders.
Urine analysis with strip tests
Strip tests (Insight, ACON Laboratories),
allowing pH and specific gravity (SG) assessment,
glucose level, presence of blood, leukocytes,
nitrites, urobilinogen, ketones, bilirubin and protein,
were used for qualitative and semi-quantitative
assessment of urine obtained from study animals. To
perform a test, strips were placed in previously
mixed urine samples, excess was filtered out and
strips left for 60 s (according to the manufacturerís
instructions after that time the result of blood and
protein presence could be considered reliable). After
that time strips were compared to the scale printed
on the package and results were recorded. 
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Histological assessment of collected urinary blad-
ders and kidneys 
The histological analysis was performed at
the Department of Anatomo-pathology of the Non-
public Healthcare Institution ÑProsmedî in
KrakÛw. Kidneys and bladders collected in course
of the post-mortem examination were washed in
normal saline and fixed for 24 hours in 8% formal
in phosphate buffer solution (PBS pH 7.4).
Collected specimens were subsequently washed
under running water for 2 h, and dehydrated in
ethanol (condensations increasing from 50 to
100%). Before embedding in paraffin, specimens
were passed through xylene solution in order to be
cleared. From xylene, specimens were transferred
to a 1 : 1 xylene and paraffin mixture and incubat-
ed at 37oC for 2 h. Then, individual tissue frag-
ments were transferred twice into pure paraffin and
incubated at 62OC. After 2 h, specimens were
embedded into paraffin blocks. After setting down
blocks were sliced with a microtome, and resulting
sections were dried on a glass slide at 37OC.
Specimens were stained with hematoxilin-eosin
(HE) in order to facilitate the histological assess-
ment of inflammation. Specimens of urinary blad-
ders and kidneys from animals receiving normal
saline (control group 3) were compared to those
from animals treated with CP/IF. 
The histological analysis was performed using
an optical (light) microscope (Delta Optical) at a
magnification of 40 × (urinary bladders) and 100 ×
(kidneys). The microscopic images were taken using
a DLT-Cam Basic 2MP microscopic camera and
DLTCamViewer software. 
Statistical analysis
Results of qualitative and semi-quantitative
urine analysis completed with strip tests were not
subject to statistical assessment. Obtained results of
vital signs and laboratory determinations of urine
and plasma were initially assessed using the
Shapiro-Wilk test, in order to verify normality of
distribution. With verified normality of distribution,
the essential statistical analysis of differences
between groups (group 1 vs. group 3, and group 2
vs. group 3) was performed using the t-Student test,
with the accepted statistical significance level of p ≤
0.05. In those cases when results verified by the ini-
tial Shapiro-Wilk test failed to meet criteria of a nor-
mal distribution, differences were tested with the
Mann-Whitney test, also with the statistical signifi-
cance level of p ≤ 0.05.
Table 1. Metabolic cage measurement - results (mean ± SD) of the living parameters of the animals  used in the experiment.
Group 1 Group 2 Group 3
Statistical analysis
CP-treated rats IF-treated rats Control rats
(p value)
1-3 2-3
Body weight[g] 248.50 ± 32.30 257.00 ± 10.89 226.6 ± 44.89 NS NS
Body temperature[OC] 36.23 ± 0.90 35.50 ± 0.25 37.43 ± 0.93 0.04 0.01
Daily water intake[mL/24h] 22.50 ± 11.47 13.50 ± 7.19 26.34 ± 4.07 NS 0.02
Daily feed intake[g/24h] 1.98 ± 1.37 4.53 ± 3.72 23.75 ± 6.16 < 0.001 < 0.001
NS - Non-significant
Table 2. The results of the estimated plasma parameters (mean ± SD) in study rats. 
Group 1 Group 2 Group 3
Statistical analysis
CP-treated rats IF-treated rats Control rats
(p value)
1-3 2-3
Na [mM/L] 141.95 ± 1.26 144.75 ± 1.95 142.06 ± 1.79 NS 0.04
Urea [mM/L] 8.97 ± 1.54 10.93 ± 2.12 6.34 ± 0.75 0.03 < 0.001
Creatinine [µM/L] 38.45 ± 7.96 34.67 ± 7.48 28.85 ± 1.77 0.05 0.05
Uric acid [µM/L] 165.82 ± 45.77 178.38 ± 21.88 157.96 ± 35.14 NS NS
NS - Non-significant
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RESULTS
Vital signs
After the end of monitoring in metabolic cages,
body weight of study animals was not significantly
different. 24 h after administration of a drug, ani-
mals receiving CP or IF had a significantly lower
body temperature compared to control animals.
Similarly, a statistically significant reduction of cir-
cadian feed consumption was found in both groups
1 and 2 compared to the control, which was proba-
bly a result of unfavorable systemic effect of CP/IF,
particularly on gastrointestinal mucosa. Moreover,
rats receiving IF consumed a significantly lower
amount of water within 24 hours post the drug
administration, compared to the control.
Detailed results of measurement of vital signs
are presented in Table 1. Considering the fact that
measurements were characterized by a normal dis-
tribution, the statistical analysis of intra-group dif-
ferences was performed using the t-Student test. 
Qualitative and semi-quantitative urinalysis with
strip tests
Values of pH and specific gravity are described
below, along with description of parameters meas-
ured in urine. A minor leukocyte count (estimated at
15 (±); n = 7) and a minor proteinuria estimated at
(+) (30 [mg/dL]; n = 5) were demonstrated in con-
trol animals. Absence of other measured compo-
nents was confirmed in their urine. 
Urine from animals receiving CP was charac-
terized by leukocytosis in 25% of cases estimated at
+ (70 [leu/µL]), in 25% at ++ (125 [leu/µL]), and in
the remaining half of cases at +++ (500 [leu/µL]).
Presence of blood was confirmed in all urine sam-
ples, estimated at +++. Similarly, proteinuria was
found in all animals in the group 1, estimated at +++
(300 [mg/dL]). Nitrites, urobilinogen, ketones,
bilirubin or glucose were found in urine from none
of CP-treated animals.
Strip urinalysis of rats treated with IF gave
similar results: no urobilinogen, ketones, bilirubin or
glucose were found, but presence of nitrites was
demonstrated in 25% of cases. Leukocytosis was
lower than that measured in the group 1: in 25% of
cases it was estimated at +/- (15 [leu/µL]), in 25% at
+ (70 [leu/µL]), and no leukocytes were found in
urine in the remaining half of cases. Presence of
blood estimated at +++ was demonstrated in half of
cases; but no hematuria was found in the other half.
Similarly to CP-treated animals, rats treated with IF
demonstrated proteinuria, estimated at +++ (300
[mg/dL]) in all cases.
Table 3. The results of the estimated urine parameters (mean ± SD) in study rats.
Group 1 Group 2 Group 3
Statistical analysis
CP-treated rats IF-treated rats Control rats
(p value)
1-3 2-3
Diuresis[mL/24 h] 16.70 ± 8.31 8.95 ± 7.49 5.85 ± 2.37 0.04 NS
Diuresis[mL/min] 0.012 ± 0.006 0.006 ± 0.005 0.004 ± 0.002 0.04 NS
pH 6.75 ± 0.29 6.13 ± 0.75 8.94 ± 0.18 < 0.001 0.002
SG [g/cm3] 1.014 ± 0.003 1.023 ± 0.006 1.011 ± 0.002 NS 0.007
Na [mM/L] 46.00 ± 10.94 80.83 ± 36.08 127.58 ± 34.67 0.004 NS
K [mM/L] 68.10 ± 27.31 159.32 ± 81.20 352.96 ± 64.66 0.004 0.004
Urea [mM/L] 414.35 ± 115.32 949.25 ± 532.44 1003.96 ± 188.91 0.004 NS
Creatinine [mM/L] 3.35 ± 1.17 6.75 ± 4.34 6.10 ± 1.10 0.008 NS
Uric acid [µM/L] 826.18 ± 321.76 1378.10 ± 401.61 1286.54 ± 296.60 0.05 NS
Urine protein [g/L] 2.5 ± 0.92 3.91 ± 1.15 0.81 ± 0.51 0.008 0.03
Na [mM/24 h] 0.78 ± 0.44 0.55 ± 0.14 0.75 ± 0.37 NS NS
K [mM/24 h] 1.09 ± 0.49 1.03 ± 0.20 2.05 ± 0.86 0.05 0.02
Urea [mM/24 h] 6.36 ± 1.91 5.72 ± 0.61 5.80 ± 2.38 NS NS
Creatinine [µM/24 h] 50.49 ± 18.12 42.21 ± 13.76 35.19 ± 13.85 NS NS
Uric acid [µM/24 h] 13.53 ± 6.82 10.58 ± 5.36 7.49 ± 3.75 NS NS
Urine protein [mg/24 h] 38.70 ± 17.12 23.57 ± 14.83 5.27 ± 4.47 0.004 0.03
NS - Non-significant, SG - specific gravity
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Parameters determined in plasma 
Considering signs of hemolysis evident in
majority of plasma samples, results of plasma potas-
sium levels had been discarded as non-reliable. 
Values of plasma parameters assessed in CP-
treated were not significantly different from control
animals, except for a statistically significant
increased urea and creatinine levels. But IF-treated
animals were characterized with a significant hyper-
natremia, increased plasma urea and creatinine lev-
els, with a statistically insignificant reduction of the
plasma uric acid level. Detailed results of measure-
ment of plasma parameters are presented in Table 2.
Considering the fact that measurements had no nor-
mal distribution, the statistical analysis of intra-
group differences was performed using the Mann-
Whitney test.
Parameters determined in urine
The circadian diuresis and the calculated
minute diuresis was significantly higher in CP-treat-
ed animals. On the contrary, IF-treated rats demon-
strated no significant difference in diuresis com-
pared to control animals. In both groups of treated
animals a significant acidosis of urine was found,
compared to the control group. Specific gravity of
urine from rats receiving IF was significantly higher
compared to the control.
Urine levels of all determined substances were
significantly lower in the group 1 (CP treatment)
compared to the control, except for protein. Protein
levels were statistically significantly higher in CP-
treated animals. IF-treated rats were characterized
by significantly lower and higher of potassium and
protein levels, respectively, compared to the con-
trol.
The analysis of circadian urine elimination of
tested substances demonstrated in both groups of
treated animals a statistically significant reduction
of potassium elimination and a significant protein-
uria. Other urine components were eliminated in
amounts similar to those observed in the control
group. 
Detailed results of measurement of plasma
parameters are presented in Table 3. Considering the
fact that measurements were characterized by a normal
distribution, the statistical analysis of intra-group dif-
ferences was performed using the t-Student test.
Values of calculated parameters: creatinine
clearance, urea clearance, fractionated sodium elim-
ination and renal failure index were not significant-
ly different in CP-treated rats compared to the con-
trol. On the contrary, comparing IF-treated animals
with the control, a statistically significant reduction
of urea clearance, FENa and RFI were found.
Creatinine clearance was an exception.
The above mentioned relationships are illus-
trated in Figures 1-4, below (graphs present median
values, quartiles and ranges for individual vari-
ables).
Figure 1. Creatinine clearance in cyclophosphamide-treated (left) and ifosfamide-treated (right) rats (no statistically significant differences
revealed in both comparisons)
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Results of histopathological analysis of urinary
bladders and kidneys
Histopathological assessment of urinary blad-
der specimens from rats receiving a single large
dose of CP demonstrated congestion with inflamma-
tory infiltration in stroma of the cystic mucosa, and
epithelium with signs of regeneration. Moreover,
clusters of dilated tubules covered by a regular cubic
epithelium and a low cylindrical epithelium were
visible in selected specimens. Urinary bladders of
animals treated with a single large dose of IF pre-
sented similar disturbances to those observed in CP-
treated rats, with additional signs of exfoliation of
the lining epithelium.
Figure 2. Urea clearance in cyclophosphamide-treated (left) and ifosfamide-treated (right) rats (p < 0.05 for Control-IF rats, non-signifi-
cant for Control-CP ones)
Figure 3. Fractional excretion of sodium (FENa) in cyclophosphamide-treated (left) and ifosfamide-treated (right) rats (p < 0.05 for
Control-IF rats, non-significant for Control-CP ones)
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Histopathological analysis of kidneys demon-
strated minor congestion in both CP and IF-treated
animals, but besides that the presentation was with-
in the normal range determined for control animals.
The samples of microscopic images of the urinary
bladders and kidneys obtained from control and
CP/IF treated rats are shown in Figures 5 and 6,
respectively.
DISCUSSION
The experiment demonstrated existence of the
following principal disorders:
1. Rats treated with a single dose of CP demon-
strated reduced body temperature and reduced circa-
dian feed consumption, with increased diuresis and
decrease of urine pH. That group presented a
reduced circadian elimination of potassium and a
significant proteinuria, as well as increased plasma
creatinine and urea levels, compared to control ani-
mals. 
2. Similarly to CP-treated rats, animals receiv-
ing a single dose of IF were also characterized by
reduced body temperature and reduced circadian
feed consumption, and by urine pH decrease.
Contrary to CP-treated animals, that group present-
ed diuresis comparable to that observed in control
animals, with a lower daily water consumption.
Administration of a single dose of IF resulted in
reduced 24-hour elimination of potassium and a sig-
nificant proteinuria, just like in case of a single dose
of CP. Similarly to animals treated with CP, admin-
istration of IF resulted in increased creatinine and
urea plasma levels. Moreover, IF-treated animals
presented reduced urea clearance values, fractionat-
ed sodium elimination and acute renal failure index.
Although being statistically significant,
reduced urine levels of all parameters determined in
CP-treated animals compared to the control group,
were rather a result of increased diuresis in that
group of rats, and not a result of a real increase of
urine elimination of those substances. Particularly,
the analysis of circadian elimination of electrolytes
and nitrogen compounds demonstrated a reduced
urine elimination of potassium only, with a signifi-
cant proteinuria in CP-treated animals (and in IF-
treated, as well). Considering those laboratory results
globally, it should be stated that renal dysfunctions
observed after administration of both CP and IF were
of functional character and were not accompanied by
any morphological injury of kidneys evident in the
histopathological assessment. Therefore, a single
exposure to oxazaphosphorines was sufficient to
cause a functional disorder of kidneys, manifested
principally by impaired tubular transport in terms of
secretion and reuptake of potassium, and ñ in case of
CP-treated animals ñ by impaired condensation of
urine. Decreased urine potassium elimination may be
Figure 4. Renal failure index (RFI) in cyclophosphamide-treated (left) and ifosfamide-treated (right) rats (p < 0.05 for Control-IF rats, non-
significant for Control-CP ones)
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associated with an expected retention of the element
in blood. That assumption could not be verified
because of hemolysis of plasma samples. Regulation
of plasma potassium levels (and consequently the
dynamics of its elimination with urine) is based
mostly on exchange of the ion between intra- and
extracellular fluid. Kidneys are a critical organ
engaged in regulation of systemic amount of potassi-
um. Within a nephron, potassium ions undergo
glomerular filtration, and are subsequently reuptaken
in proximal tubules and in the loop of Henly. The
final urinary elimination of majority of potassium
ions depends on the active secretion of the ion by
cells of distal and collecting tubules, determined by
increased plasma levels of the electrolyte, increased
Na+- K+/H+ exchange with participation of the
aldosterone-regulated ATPase in basal-lateral mem-
brane and a direct secretion of the ion into urine (29,
30). Considering a reduced circadian potassium
elimination observed in study animals, a thesis may
be formulated that both CP and IF contribute to dys-
function of distal and collecting tubules. 
Urine acidification is an additional argument
supporting tubulopathy caused by CP/IF. The
process is also associated with potassium metabo-
lism, as mentioned above (K+/H+ exchange). In
general terms it may be stated that two processes
occur in nephrons: reuptake of alkalis and secretion
of acids. The first one takes place in proximal
tubules, and the other one in distal tubules (31).
Secretion of H+ ions into urine takes place via the
mentioned above antiport K+/H+ ñ ATPase and the
luminal pump H+ ñ ATPase, and a final acidifica-
tion of urine depends also on phosphate and ammo-
nia buffer (32, 33). It seems that CP and IF may
impair those mechanisms, leading to final reduction
of urine pH and increased potassium reuptake. 
Moreover, CP-treated animals demonstrated
polyuria, which ñ in face of circadian water con-
sumption comparable to that observed in the control
group ñ may constitute another argument in favor of
dysfunction of distal and collecting tubules.
Reuptake of water and final condensation of urine
depends on aquaporins ñ integral proteins of water
Figure 5. Light microscopy of the urinary bladders ñ in control (left) and in the CP/IF (right) rats
Figure 6. Light microscopy of the kidneys ñ in control (left) and in the CP/IF (right) rats
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channels induced in apical membranes of collecting
tubules by antidiuretic hormone (34). Therefore,
polyuria observed in the group of rats receiving a
nephrotoxic dose of CP may be a result of impair-
ment of that mechanism. That observation is con-
trary to literature reports indicating a possible devel-
opment of Ñsyndrome of nephrogenic syndrome of
inappriopriate antidiuresisî induced by CP as a
result of increased expression and hyperactivity of
aquaporins in collecting tubules of rats following
administration of the dose of 12-96 mg/kg b.w. (35)
or 25-50 mg/kg b.w. of CP (36), in 12-72 h after
administration of cyclophosphamide. The quoted
studies indicate also that the effect may be ADH-
independent, and time- and dose-dependent, there-
fore the effect of CP on the volume of diuresis has
to be more precisely defined. 
A significant proteinuria was demonstrated in
both treated groups. Pathogenesis of that disorder
seems complex and may be a result of above men-
tioned dysfunction of renal tubules, or be a conse-
quence of other disorders. According to the general
pathophysiological classification, proteinuria may
be of prerenal character (overload), renal character
(glomerular or tubular) or extrarenal character (e.g.,
inflammatory, neoplastic or obstructive disturbances
of the lower urinary tract) (37, 38). Therefore, pres-
ence of increased urinary elimination of protein in
study rats may be a result of impairment of resorp-
tive function of tubules, but considering presence of
oxazaphosphorine-induced inflammatory changes in
the urinary bladder, it may be also of extrarenal
character.
Reduced values of both FENa and RFI were also
demonstrated in IF-treated rats. Fractional excretion
of sodium is defined as the amount of sodium final-
ly eliminated with final urine after the phase of
glomerular filtration (39, 40). The renal failure
index describes a relationship between the plasma
creatinine level and urine sodium and creatinine lev-
els (41). Both FENa and RFI are currently regarded
modern laboratory parameters of acute kidney injury
(AKI) ñ the term used currently in place of former-
ly used ìacute renal failureî. The disorders is a
result of pre-, intra- and extrarenal processes leading
to development of acute tubular necrosis and finally
to irreversible failure of the organ (42, 43). Clinical
guidelines recommend the diagnosis of AKI, along
with a possible pathophysiological differentiation
into ante- and intrarenal form, based on values of the
above mentioned values of FENa and RFI, that are
decreased in the prerenal form. Although clinical
observations cannot be uncritically translated into
experimental conditions, reduced values of both
FENa and RFI were observed in rats receiving a sin-
gle nephrotoxic dose of IF, compared to correspon-
ding values in control animals (Figs. 3 and 4).
Reduced FENa in IF-treated animals was accompa-
nied by reduced circadian urinary sodium elimina-
tion [mM/24 h]. Although no statistical significance
was reached in comparison to control animals, a
trend could be observed. No FENa or RFI reduction
was demonstrated in animals receiving a single,
nephrotoxic dose of CP. Therefore, those results
may suggest development of functional AKI caused
by IF, with normal diuresis comparable to that
observed in the control, and a normal creatinine
clearance, which does not exclude the presence of
AKI ñ the disorder may occur in oliguric form or
with a paradoxical normal diuresis (44).
Confirmation of the pathophysiological prerenal
character of AKI in those animals (as evidenced by
reduced FENa and RFI compared to the control), and
particularly of the potential mechanism responsible
for prerenal functional kidney injury requires some
more detailed studies.
CONCLUSIONS
Multiple renal dysfunctions resulted from
oxazaphosphorines administration were reported ñ a
combination of glomerular, proximal or distal tubu-
lar damage, Fanconi syndrome and reversible AKI
or a permanent chronic kidney disease were
revealed. These disturbances are characterized by a
considerable variability in the onset, clinical mani-
festation, severity and reversibility and dependent
on the dose and time of the therapy (18-20).
Renal dysfunctions observed in study animals
are consistent with the above mentioned literature
data. Described disorders developing as a result of
administration of a single, nephrotoxic dose of
CP/IF also suggest a dysfunction of mostly distal
and collecting tubules, with absence of morphologi-
cal changes in kidneys. Proteinuria, urine acidifica-
tion with reduced circadian elimination of potassium
and increased plasma levels of creatinine and urea
were demonstrated as a result of a single exposure to
nephrotoxic doses of CP/IF. The commonly recog-
nized lower nephrotoxicity of cyclophosphamide
was also confirmed in this study. No laboratory fea-
tures of AKI (RFI, FENa) were demonstrated follow-
ing administration of a single dose, contrary to IF-
treated rats. However, a significant polyuria was
observed in case of CP, in place of the literature-
reported antidiuresis syndrome, which may be a
result of different methodology of the study, differ-
ent dosage and observation time.
Nephrotoxicity of a single dose of cyclophosphamide and... 1589
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